Data Insights

Botensilimab by Agenus for Metastatic Colorectal Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Metastatic Colorectal Cancer

Data Insights

Botensilimab by Agenus for Colorectal Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Colorectal Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Colorectal Cancer

Data Insights

Botensilimab by Agenus for Bladder Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Bladder Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Bladder Cancer

Data Insights

Botensilimab by Agenus for Gastric Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Gastric Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Gastric Cancer

Data Insights

Botensilimab by Agenus for Prostate Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Prostate Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Prostate Cancer

Data Insights

Botensilimab by Agenus for Breast Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Breast Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Breast Cancer

Data Insights

Botensilimab by Agenus for Metastatic Renal Cell Carcinoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Metastatic Renal Cell Carcinoma

Data Insights

Botensilimab by Agenus for Esophageal Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase II for Esophageal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Esophageal Cancer

Data Insights

Botensilimab by Agenus for Endometrial Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Endometrial Cancer

Data Insights

Botensilimab by Agenus for Metastatic Pancreatic Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Metastatic Pancreatic Cancer

Data Insights

Botensilimab by Agenus for Hepatocellular Carcinoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Hepatocellular Carcinoma

Data Insights

Botensilimab by Agenus for Cervical Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Cervical Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Cervical Cancer

Data Insights

Botensilimab by Agenus for Ovarian Cancer: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Ovarian Cancer

Data Insights

Botensilimab by Agenus for Leiomyosarcoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Leiomyosarcoma

Data Insights

Botensilimab by Agenus for Angiosarcoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Angiosarcoma. According to GlobalData, Phase I drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Angiosarcoma

Data Insights

Botensilimab by Agenus for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Pancreatic Ductal Adenocarcinoma

Data Insights

Botensilimab by Agenus for Renal Cell Carcinoma: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Renal Cell Carcinoma

Data Insights

Botensilimab by Agenus for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Metastatic Castration-Resistant Prostate Cancer (mCRPC). According to...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Data Insights

Botensilimab by Agenus for Sarcomas: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase III for Sarcomas. According to GlobalData, Phase III drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Sarcomas

Data Insights

Botensilimab by Agenus for Solid Tumor: Likelihood of Approval

Botensilimab is under clinical development by Agenus and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Botensilimab in Solid Tumor